Similar articles

• ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

  Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A. Feldinger K, et al. Oncotarget. 2014 Aug 30;5(16):6633-46. doi: 10.18632/oncotarget.1955. Oncotarget. 2014. PMID: 24952873 Free PMC article.
• Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.

  Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C, Katiyar K, Bradley J, Abremski K, Stow M, Rupar M, Zhuo J, Li YL, Lin Q, Burns D, Xu M, Zhang C, Qian DQ, He C, Sharief V, Weng L, Agrios C, Shi E, Metcalf B, Newton R, Friedman S, Yao W, Scherle P, Hollis G, Burn TC. Liu PC, et al. Cancer Biol Ther. 2006 Jun;5(6):657-64. doi: 10.4161/cbt.5.6.2708. Epub 2006 Jun 14. Cancer Biol Ther. 2006. PMID: 16627989
• Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro.

  Pham DH, Kim JS, Kim SK, Shin DJ, Uong NT, Hyun H, Yoon MS, Kang SJ, Ryu YJ, Cho JS, Yoon JH, Lee JS, Cho D, Lee SH, Park MH. Pham DH, et al. Anticancer Res. 2017 Oct;37(10):5507-5513. doi: 10.21873/anticanres.11981. Anticancer Res. 2017. PMID: 28982863
• The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.

  Pruessmeyer J, Ludwig A. Pruessmeyer J, et al. Semin Cell Dev Biol. 2009 Apr;20(2):164-74. doi: 10.1016/j.semcdb.2008.09.005. Epub 2008 Sep 18. Semin Cell Dev Biol. 2009. PMID: 18951988 Review.
• ADAM10 as a target for anti-cancer therapy.

  Moss ML, Stoeck A, Yan W, Dempsey PJ. Moss ML, et al. Curr Pharm Biotechnol. 2008 Feb;9(1):2-8. doi: 10.2174/138920108783497613. Curr Pharm Biotechnol. 2008. PMID: 18289051 Review.